Thursday, 21 Mar 2019

You are here

Dendrimer Nanocarrier Delivers IGF-1 to Degenerative Cartilage

Researchers from MIT have developed a novel treatment for osteoarthritis (OA) by using dendrimer-based nanocarriers to deliver insulin-like growth factor 1 (IGF-1) to chondrocytes within joint cartilage and in animal models have shown when these nanocarriers injected into rat knees in models of OA, they reduced cartilage degeneration.

Dendrimers are repetitively branched molecules containing highly symmetric, spherical compounds. In these experiments the nanocarriers allow the dendrimer–IGF-1 to penetrate and be retained by full-thickness bovine cartilage ex vivo. 

One of the challenges of delivering therapies (e.g., anabolic growth factors) to cartilage is that the tissue is that the chondrocytes reside deep within dense, anionic cartilage tissue. To overcome this biological barrier, they conjugated a IGF-1 (growth factor) to a cationic nanocarrier for targeted delivery to chondrocytes and retention within joint cartilage after direct intra-articular injection.

Amine terminal polyamidoamine (PAMAM) dendrimers were integrated with variable molar ratios of poly(ethylene glycol) (PEG) to control surface charge. Using variably PEGylated dendrimers, an optimal formulation showing 70% uptake into cartilage tissue and 100% cell viability was selected.

When conjugated to insulin-like growth factor 1 (IGF-1), the dendrimer penetrated bovine cartilage of human thickness within 2 days and enhanced therapeutic IGF-1 joint residence time in rat knees by 10-fold for up to 30 days.

Using a rat model of knee OA, a single injection of dendrimer–IGF-1 rescued cartilage and bone more effectively than free IGF-1. Dendrimer–IGF-1 reduced width of cartilage degeneration by 60% and volumetric osteophyte burden by 80% relative to untreated rats at 4 weeks after surgery.

These results suggest improve pharmacokinetics and efficacy of disease-modifying osteoarthritis drugs in the clinic.

This study shows that using that PEGylated PAMAM dendrimer nanocarriers with disease-modifying agents to target chondrocytes may be therapeutic in knee OA.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Risky Painkillers Commonly Prescribed for Osteoarthritis

Published guidelines warn that treating osteoarthritis (OA) with opioids and benzodiazepines can boost patients' risk of falling. Nevertheless, physicians in a large health system were prescribing those drugs for the condition nearly a third of the time, often in the vulnerable elderly, according to a study reported here.

Tramadol May be Associated with Increased Mortality in Osteoarthritis

JAMA reports that tramadol use in adults with osteoarthritis (OA) may be associated with increased all-cause mortality (compared with nonsteroidal anti-inflammatory drugs).

TKR - One or Two at a Time?

His would-be surgeon tried mightily to talk him out of a bilateral knee replacement. At 340 pounds, the patient's BMI -- above 43 -- was a significant contraindication. 

But the patient -- Nick Yphantides, MD, chief medical officer for California's San Diego County -- told MedPage Today he "aggressively" insisted, threatening to find another surgeon if he had to.

Older Men Less Likely to be Assessed and Treated for Osteoporosis

A study from the University of Washington in Seattle find that men with osteoporosis were less likely to be assessed by dual-energy X-ray absorptiometry (DXA); vitamin D measurements and were less like to receive calcium/vitamin D and bisphosphonate prescriptions. 

Hip Replacements Lasting 25 Years

Lancet reports that, based on a literature review and metanalysis, patients and surgeons can expect a hip replacement to last 25 years in around 58% of patients.

In the USA, there is an estimated 400,000 total hip arthroplasties (THA) annually. UK invesigators set out to answer the question: how long does a hip replacement last?